A Guide to Biotechnology Law and Business

Contents

Table of Cases xvii
Acknowledgments xix

Chapter 1 An Introduction to Biotechnology Law and Business 3
§1.0 Biotechnology: Infinite Promise and Infinitely Challenging 3
§1.1 The Purpose of This Book 4
§1.1(A) An Overview of This Book 4
§1.2 What is Biotechnology? 5
§1.2(A) The Scope of the Biotechnology Industry 6
§1.2(B) Applications of Biotechnology: Human Health 7
§1.2(B)(1) Human Therapeutics 8
§1.2(B)(2) Diagnostics for Human Disease 11
§1.2(B)(3) Vaccines 12
§1.2(C) Applications of Biotechnology: Agriculture 12
§1.2(D) Industrial Applications of Biotechnology 13
§1.3 Summary: The Life Cycle of Biotechnology and the Lawyer's Role 14

Chapter 2 A Primer on the Basic Science and Applications of Biotechnology 19
§2.0 Modern Molecular Biology and Immunology 19
§2.1 DNA and the Genetic Code 19
§2.1(A) From DNA to RNA to Protein: The Central Dogma of Molecular Biology (Now Known to be False!) 20
§2.1(B) Genes: The Recipe for a Protein 21
§2.1(C) Genes, Proteins, and Splice Variants 21
§2.1(D) Putting It All Together: Genomes, Genotypes, and Phenotypes 22
§2.2 Prokaryotes, Eukaryotes, and Viruses 23
§2.2(A) Viruses 24
§2.2(B) Bacteria (Prokaryotes) 24

§2.2(C) Eukaryotes 25
§2.3 Introductory Genetic Engineering for Beginning Non-Biologists 25
§2.3(A) Gel Electrophoresis 26
§2.3(B) DNA Sequencing 27
§2.3(C) Cloning Genes 28
§2.3(D) Polymerase Chain Reaction 29
§2.4 An Introduction to Immunology (and Monoclonal Antibodies) 29
§2.5 Applications of Genetic Engineering in Health Care 34
§2.5(A) Genetically Engineered Vaccines 34
§2.5(B) Diagnostic Gene Probes 35
§2.5(C) Therapeutic Applications of Genetic Engineering 36
§2.5(D) Genetic Engineering and Human Gene Therapy 38
§2.6 Applications of Monoclonal Antibody Technology in Health Care 40
§2.6(A) Therapeutic Uses of Monoclonal Antibodies 41
§2.7 Genetic Engineering Applications in Agriculture and Industry 42
§2.8 Summary 43

Chapter 3 Technology Transfer: The University-Industry Connection 45
§3.0 Introduction: Universities and Research Institutes—Where Biotechnology Is Born 45
§3.1 An Introduction to the Bayh-Dole Act: Transfer of Technology Developed with Federal Research Funding 46
§3.2 The Requirements of Bayh-Dole for Universities 48
§3.2(A) Assignment of Rights 48
§3.2(B) Sharing Proceeds 50
§3.3 The University Office of Technology Transfer (OTT): Functions and Models 51
§3.3(A) Disclosure 51
§3.3(B) Evaluation 52
§3.3(C) Marketing 53
§3.3(D) Licensing 55
§3.3(E) Monitoring and Enforcement 55
§3.4 Alternative Models of Technology Transfer: Scripps, the NIH Guidelines, and Post-NIH Guidelines Developments 56
§3.4(A) The Scripps Research Institute (TSRI) Significant Relationship Model 56
§3.4(B) The NIH Guidelines: Developing Sponsored Research Agreements: Considerations for Recipients of NIH

Research Grants (59 FR 32997-02, Monday, June 27, 1994) ("NIH Sponsored Research Guidelines") 58
§3.5 Licensing a University Invention (Also a Few Tips on Negotiation) 60
§3.5(A) Licensed Technology 62
§3.5(B) Sublicensing 63
§3.5(C) Field of Use, Geographic Territory, and Exclusive Versus Non-Exclusive 64
§3.5(D) Royalties, Licensing Fees, and Milestone Payments 66
§3.5(E) The Bottom Line on University Licensing 67
§3.6 Sponsored Research Agreements 67
§3.6(A) The Description of the Research 67
§3.6(B) Time for Review before Publication 68
§3.6(C) Sponsor's Rights to Inventions Resulting from the Sponsored Research 68
§3.7 Conclusion: University Technology and Biotechnology 69

Chapter 4 Intellectual Property (IP) Protection for Biotechnology 71
§4.0 Introduction: The Need for Patents and the Patentability of Biotechnology 71
§4.1 Patents and Trade Secrets: Choosing a Method for Protection 73
§4.2 Differences Between U.S. and Foreign Patent Law 75
§4.3 Patentable Subject Matter 77
§4.4 New and Useful: The Requirement of Utility 80
§4.5 Novelty and Publication 82
§4.6 Nonobviousness 84
§4.6(A) Secondary Evidence of Nonobviousness 88
§4.7 Written Description, Enablement, and Best Mode: The Requirements of §112 89
§4.8 Other Special Problems for Biotechnology Patents 93
§4.8(A) Protection from Foreign Competition 93
§4.8(B) Biotechnology Products Derived from Human Tissue 95
§4.8(C) Patent Protection for Stem Cell Research and Development 96
§4.9 Biotechnology Patents: Moral and Ethical Issues 97
§4.9(A) The Rights of Indigenous Peoples 97
§4.9(B) Patent Protection for Drugs Derived from Traditional Remedies 99

§4.9(C) Patenting Animals: Beyond Patentable Subject Matter to Agricultural Policy and Animal Rights 99
§4.10 Broad Patent Claims to Drug Targets 100
§4.11 Patent Infringement and the Doctrine of Equivalents 102
§4.11(A) Reverse Equivalents 104
§4.11(B) Unexpected Results 105
§4.12 Conclusion: Future Directions for Biotechnology Patent Law 105
§4.12(A) International Patent Issues 106
§4.12(B) Life-Saving Pharmaceuticals in Developing Countries 106
§4.12(C) Scientific Progress, the Human Genome Initiative, and Changes in Patent Law 106

Chapter 5 Biotechnology Business Strategy 109
§5.0 Introduction (Including a Brief History of Biotech Business Models) 109
§5.1 Strategic Planning for the New "Hybrid" Biotechnology 112
§5.1(A) The Role of Markets in Strategic Planning 113
§5.1(B) Minimizing Risk in Clinical Development: Animal Models, Clinical Trial Costs (Sizes and Duration), Clear Pathways, and Unmet Medical Needs 115
§5.2 Integrating Regulatory Strategy and Market Issues 119
§5.3 Financing Biopharmaceutical Development: Considerations and Strategy 120
§5.4 Summary: The Multiple Strands of a Biotech Business Plan 125

Chapter 6 Financing the Process of Development 129
§6.0 Introduction 129
§6.1 A Brief Introduction to Corporations and Securities: (The MBAs and Lawyers May Wish to Skip This Section) 130
§6.2 Selling Securities: Caveat Vendor 132
§6.3 In the Beginning: Is There an Angel in the House? 132
§6.4 Venture Capital Financing Issues 134
§6.4(A) Due Diligence 135
§6.4(B) Valuation of the Investment (and the Company) 137
§6.4(C) Capital Structure: Authorized Shares 139
§6.4(D) Stock Options Plans 140
§6.4(E) Stages of Venture Capital Investment 141
§6.4(F) Anti-Dilution 142

§6.5 Beyond the First Round: Licensing and Corporate Strategic Alliances 142
§6.5(A) The Framework for a Strategic Alliance 144
§6.5(B) Timing of Alliances and the Impact on Valuation 145
§6.5(C) Foreign Partnerships 148
§6.6 Introduction to the Public Offering 149
§6.6(A) The Decision to Go Public 149
§6.6(B) Preparing the Public Offering: The Letter of Intent 151
§6.6(C) Going Public: The Team 151
§6.6(D) Going Public: Due Diligence 152
§6.6(E) Going Public: Filing the Registration Statement 153
§6.6(F) Going Public: The Effective Date and the Closing Date 154
§6.6(G) Going Public: The Quiet Period 155
§6.6(H) Going Public: Lock-Up Periods and the PSLRA "Safe Harbor" 156
§6.7 Conclusion: Biotechnology Finance as a Four-Dimensional Rubik's Cube 158

Chapter 7 An Overview of the Regulation of Biotechnology 161
§7.0 Introduction 161
§7.1 History of the Regulation of Genetic Engineering 163
§7.2 Regulation Under the NIH Recombinant DNA Advisory Committee Guidelines (NIH-RAC) 164
§7.3 The FDA and Human Health Care Applications of Biotechnology 168
§7.3(A) The FDA Approval of Human Therapeutics and Diagnostics 168
§7.3(B) The FDA and New Animal Drugs 171
§7.4 The EPA and Agricultural Biotechnology 172
§7.4(A) EPA's FIFRA Procedures for Field Testing Genetically Engineered Organisms 173
§7.4(B) The FIFRA Standard for the Approval of Pesticides 174
§7.5 EPA'S Regulation of Non-Agricultural Biotechnology—TSCA 175
§7.5(A) TSCA's Scope, Procedures, and Standards 176
§7.5(B) Requirement of a Premanufacture Notice (PMN) 177
§7.6 The USDA and Agricultural Biotechnology 178
§7.6(A) USDA's Regulation of Veterinary Biological Products—VSTA 179

§7.6(B) USDA's Regulation of Genetically Engineered Microorganisms and Plants—PPA 181
§7.6(C) The Scope, Standards, and Procedures of the PPA 182
§7.7 The Regulation of Food Products from Genetically Engineered Plants 183
§7.7(A) Adulterated: The First Concept of Food Safety 183
§7.7(B) Food Additive: Added Substances That Do Not Adulterate 184
§7.7(C) Generally Recognized as Safe (Between Additive and Adulteration) 185
§7.7(D) Foods Derived from New Plant Varieties Created by Genetic Engineering—the FDA Statement of Policy 187
§7.7(E) Food Plants Engineered to Produce a Biopesticide or Treated with a Biotechnology Derived Biopesticide 192
§7.7(F) Conclusion: Risk Perception and Food Biotechnology 193

Chapter 8 Special Regulatory Issues—FDA Regulation of Drugs, Biologics, and Devices 197
§8.0 Introduction 197
§8.1 Regulatory Strategy: An Introductory Example 199
§8.2 The FDA Structure and Statutory Authority for Drugs and Biologics (With a Brief Word about Devices) 200
§8.2(A) A Brief Excursion into the Distinction between Drugs and Biologics 201
§8.2(B) A Brief Word about Devices 205
§8.3 Stages of Drug Development and Drug Development Strategy 206
§8.3(A) From Preclinical Decision Making to NDA 209
§8.3(A)(1) The Five Key Parameters of Strategic Success: FDA Approval 210
§8.3(A)(2) Optimal Indication 210
§8.3(A)(3) The Shortest Possible Time 210
§8.3(A)(4) Conserving Scarce Resources: Time and Money 210
§8.3(A)(5) Planning for Reimbursement 211
§8.3(B) Strategic Issues in the Development Process and the Terms of Success 211
§8.3(B)(1) The Preclinical Development Process and the Optimal Indication 212
§8.3(B)(2) Conserving Time and Money 214
§8.3(B)(3) Planning for Reimbursement 216

§8.3(C) Drug Development Strategy: Learning from the Mistakes of Previous Companies 216
§8.3(D) Conclusion: Planning the Clinical Development of a New Therapeutic Begins at the Early Preclinical Stage 220
§8.4 A Practical Guide to Clinical Trials and the NDA 220
§8.4(A) The New Drug Application or Product License Application 222
§8.4(B) Beyond Approval: Post-Marketing Issues 225
§8.4(C) Reporting Adverse Drug Experiences (ADEs) 226
§8.5 Accelerated Approval and Early Access to Unapproved Drugs: Drugs for Severely Debilitating and Life Threatening Illnesses 227
§8.5(A) Fast Track, Accelerated Approval, and Priority Review 227
§8.5(B) Early Access to Experimental Drugs 229
§8.6 Product Exclusivity and the FDA: Orphan Drugs, Patent Term Extension, and Pediatric Study Extensions 231
§8.6(A) The Orphan Drug Act 231
§8.6(B) Patent Term Restoration 233
§8.6(C) Pediatric Study Patent Extensions 235
§8.7 "Generic Biopharmaceuticals" 237
§8.8 Advertising and Promoting Prescription Drugs (Herein Also a Brief Word about Dietary Supplements-DSHEA) 241
§8.8(A) The Legal Background of the FDA's Marketing and Promotion Regulation 241
§8.8(B) Marketing to Physicians and Formulary Committees 243
§8.8(C) Direct-to-Consumer (DTC) Advertising in Print and by Electronic Media 245
§8.9 DSHEA—Anything Goes (Almost) 247
§8.10 Postscript: International Pharmaceutical Regulation and Harmonization 253

Chapter 9 Ethical Perspectives on New Ethical Dilemmas for Biotechnology 257
§9.0 Introduction 257
§9.1 The Scientific Advances and Ethical Challenges to Biotechnology Research and Development 258
§9.2 Ethical Frameworks and *A Theory of Justice* 260
§9.3 Applying the Frameworks to the Problems 263
§9.3(A) Bioterrorism and Restraints on Research and Publication 263

§9.3(B) Balancing Incentives for Pharmaceutical Innovation against Affordability and Access for Persons with Medical Needs 265
§9.3(C) Echazabal and Workplace Genetic Testing: The Law and Ethics of Protecting Workers against Risks 266
§9.3(C)(1) The Legality of Protecting Workers against Risks to Their Own Health 267
§9.3(C)(2) *A Theory of Justice* and Workplace Genetic Testing 269
§9.4 Embryonic Stem Cell Research 274

Chapter 10 Special Regulatory Issues: Human Gene Therapy 277
§10.0 Introduction to Gene Therapy: At the Edge of a New Era in Medicine 277
§10.1 What is Gene Therapy? 278
§10.1(A) Candidate Diseases for Gene Therapy 280
§10.1(B) Selecting Appropriate Target Cells 281
§10.1(C) Methods for Delivering Therapeutic Genetic Material 281
§10.2 Risks of Gene Therapy 284
§10.2(A) The Risk of Producing Replication-Competent Viruses 285
§10.2(B) The Pathogenicity of Viral Vectors 286
§10.2(C) Summary: Risks of Gene Therapy 288
§10.3 The Regulatory Framework for Gene Therapy 289
§10.3(A) Notification of the NIH-RAC 289
§10.3(B) Appendix M and the NIH's Principal Concerns 290
§10.3(C) FDA Review of Gene Therapy Protocols 291
§10.4 The Ethical Debate over Gene Therapy 292
§10.4(A) General Limitations on Somatic Cell Gene Therapy 293
§10.4(B) Ethical Issues Surrounding Germ-Line Gene Therapy 294
§10.4(C) The Ethical Problem of Access to Gene Therapy 297
§10.5 Conclusion 298

Chapter 11 Liability for Biotechnology Products 299
§11.0 Introduction 299
§11.1 A Basic Overview of Negligence 300
§11.1(A) Violation of a Statute or Regulation as Negligence *Per Se* 301
§11.1(B) The Relevance of Custom to Negligence 302
§11.1(C) General Evidence of Reasonable Care 303
§11.2 An Introduction to Strict Product Liability 304

§11.2(A) Defective Condition Unreasonably Dangerous 305
§11.2(B) Manufacturing Defect 305
§11.2(C) Design Defect 306
§11.2(D) Failure to Warn 308
§11.2(E) Preemption of Liability by FDA Approval: A Complicated Tale 309
§11.3 Legal Cause: A Problem in Both Negligence and Strict Liability 311
§11.3(A) Expert Testimony in Product Liability Cases 312
§11.4 The National Vaccine Injury Compensation Program: 42 U.S.C. §300aa-1 *et seq.* (2006): One Answer to the Causation Conundrum 315
§11.5 Drugs, Vaccines, and Other Human Therapeutics as Unavoidably Unsafe: Restatement (Second) of Torts §402A Comment k 318
§11.6 Restatement of Torts (Third) and Product Liability Reform 320
§11.7 Liability for Biotechnology in Other Contexts: Beyond Product Liability for Drugs, Vaccines, and Medical Devices 322
§11.7(A) Liability in the Workplace 322
§11.7(B) Liability for Biotechnology Pesticides 327
§11.7(C) Liability for Food Products Produced by Biotechnology 328
§11.7(D) Liability for Other Biotechnology Products in Industry and the Environment 331
§11.8 Conclusion 332

Index 333